Labcorp (LH) Tops Q2 EPS by 26c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St futures gain on Iran ceasefire hopes; earnings in focus
- Oil prices firm as investors weigh fresh attacks against potential US-Iran ceasefire
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Labcorp Announces 2022 Second Quarter Results
July 28, 2022 7:00 AM EDTCompany To Spin-Off Clinical Development Business
Revenue: Q2 of $3.7 billion versus $3.8 billion last year Diluted EPS: Q2 of $3.87 versus $4.76 last year Adjusted EPS: Q2 of $4.96 versus $6.13 last year Free Cash Flow: Q2 of $429 million versus $390 million last year Launched innovative diagnostics for skin cancer, neurodegenerative disease, fertility and COVID-19 Full-Year 2022 Guidance: Adjusted EPS raised to $19.00 to $21.25BURLINGTON, N.C.--(BUSINESS... More
